SAVSU® Technologies Receives World Health Organization Approval for New Long-Range Vaccine Carrier

Santa Fe, NM, May 5, 2014/PRNNewswire/– SAVSU Technologies, an innovative designer and manufacturer of high performance passive storage and transport containers for temperature sensitive biologics and pharmaceuticals, today announced the PQS Certification by the World Health Organization for its PHD™ container series.

The reusable PHD line is designed for the shipment of biological materials, which must be maintained at 2-8˚C and or controlled room temperature (CRT). The PHD line is designed for small volume shipments from a single dose to 3 liters. Utilizing patent pending antifreeze technology, the PHD reduces the risk of freezing 2-8˚C shipments while the nanoporous insulation allows for extended shipping periods, giving greater product safety assurance in remote or extremely hot areas.

Bruce McCormick, President of SAVSU Technologies and developer of the PHD container commented on the certification saying, “SAVSU is very pleased to see the PHD container approved by the World Health Organization’s Performance, Quality and Safety process (PQS). This certification will allow our product to be accessed by organizations world wide that depend on these qualifications to safely transport vaccines to those in need.”

McCormick continued by explaining, “The PHD is a long-range vaccine carrier designed for real world applications. It’s rugged, reusable, simple to use and extremely high performance design allows for the practical expansion of immunization programs while also helping reduce the overall cost of delivery.”

The PHD is only one of the innovative products SAVSU has developed. In April 2014 at the 20th Annual Meeting of the International Society for Cellular Therapy in Paris, France, SAVSU launched the EVO™ controlled temperature container as part of an exclusive joint marketing venture with BioLife Solutions, the leading developer and supplier of biopreservation tools to the regenerative medicine, biobanking, and pharmaceutical industries. EVO is the world’s first smart shipper designed to continuously monitor a broad range of critical conditions of the payload and the location of the shipment. This data is uploaded in real time to a cloud-based web portal and a mobile application currently in development.

The EVO will be available exclusively through the biologistexsm service, from BioLife Solutions. McCormick commented “We are excited to work with BioLife Solutions as they are a world leader in the field of biopreservation and their expertise, combined with our technology can significantly help biotech companies move faster towards commercialization of their life saving products.”

We believe the promise of cell and gene therapies starts with the integrity of a single cell

Advancing the future of cell and gene therapy

The human body can heal itself. Cell and gene therapies are designed to augment the patient’s ability to fight disease but only if the living cells behind those therapies remain viable and functional throughout the production processes. At BioLife Solutions, our mission is to protect the integrity of cells and provide trusted tools, services, and expertise that can enable our customers to advance the development and delivery of cell and gene therapies. We believe the future of cell and gene therapies hinges on the integrity of every single cell and we are here to protect that promise.

We understand the technical demands of bioprocessing in this field, and our advanced biopreservation expertise, cell culture optimization products, innovative storage systems, and closed-system manufacturing solutions are designed to enhance process efficiency, maintain cellular viability, and ensure reproducibility at every stage. Whether scaling up from R&D, navigating clinical trials or optimizing cryopreservation protocols for commercial production, we provide the tools and experience to streamline your workflow and safeguard your therapies.

Work with experts who understand your biopreservation challenges

Notch-Right-25px
Notch-Bottom-25px

Collaborative and comprehensive CDMO support

At BioLife Solutions, we partner with leading contract development and manufacturing organizations (CDMOs) to enhance their biopreservation and cell processing capabilities. By providing advanced tools, regulatory support, and process optimization strategies, we empower CDMOs to better serve therapy developers, ensuring quality, consistency, and scalability in cell therapy manufacturing.

Regulatory
readiness

Navigating the complex regulatory landscape of cell and gene therapy requires a proactive approach. BioLife Solutions offers experienced regulatory support to help prepare your biopreservation and cell processing methods to meet global standards. From IND and BLA submissions to compliance with GMP, FDA, and EMA guidelines, our solutions help streamline approval pathways.

Notch-Left-25px
Notch-Bottom-25px

STORE

CellSeal®
CryoCase

Alleviate CGT container challenges like fracture risk, bag burping or high rates of particulates

Notch-Right-25px
Notch-Bottom-25px

Data-driven
decision making

Stay ahead with our comprehensive Evidence Library, a curated collection of scientific publications, white papers, and case studies demonstrating the efficacy of BioLife Solutions’ technologies. Access peer-reviewed research, real-world application data, and expert insights to support your bioprocessing and regulatory strategies.

Insights

May 21, 2025

Designing the Ideal Cryostorage Container for CGT

April 18, 2025

The Cell Summit ’25: A Must-Attend Event for Innovators in Cell & Gene Therapy

March 27, 2025

Optimizing Biopreservation Strategies for Apheresis-Derived Cells in Immunotherapeutic Applications

February 19, 2025

How to prepare early for regulatory submissions from IND to BLA

Preserve, protect and expand cell performance

Mastering
Biopreservation

Ensure Regulatory Submission Readiness

Automate & Close
CGT Processes

Protect & Expand
Cell Performance